190 related articles for article (PubMed ID: 26556482)
1. Persistence and concomitant medication in patients with overactive bladder treated with antimuscarinic agents in primary care. An observational baseline study.
Sicras-Mainar A; Navarro-Artieda R; Ruiz-Torrejón A; Sáez-Zafra M; Coll-de Tuero G
Actas Urol Esp; 2016 Mar; 40(2):96-101. PubMed ID: 26556482
[TBL] [Abstract][Full Text] [Related]
2. Use of health care resources and associated costs in non-institutionalized vulnerable elders with overactive bladder treated with antimuscarinic agents in the usual medical practice.
Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R; Aguado-Jodar A; Ruíz-Torrejón A
Actas Urol Esp; 2014 Oct; 38(8):530-7. PubMed ID: 24630426
[TBL] [Abstract][Full Text] [Related]
3. Impact of Loss of Work Productivity in Patients with Overactive Bladder Treated with Antimuscarinics in Spain: Study in Routine Clinical Practice Conditions.
Sicras-Mainar A; Navarro-Artieda R; Ruiz-Torrejón A; Sáez-Zafra M; Coll-de Tuero G
Clin Drug Investig; 2015 Dec; 35(12):795-805. PubMed ID: 26464261
[TBL] [Abstract][Full Text] [Related]
4. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
Wagg A; Compion G; Fahey A; Siddiqui E
BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents.
Sánchez-Ballester F; Miranda P; Lizarraga I; Rejas J; Arumi D
Actas Urol Esp; 2014 Apr; 38(3):156-63. PubMed ID: 24119382
[TBL] [Abstract][Full Text] [Related]
6. Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis.
Sicras-Mainar A; Rejas J; Navarro-Artieda R; Aguado-Jodar A; Ruiz-Torrejón A; Ibáñez-Nolla J; Kvasz M
Int Urogynecol J; 2014 Apr; 25(4):485-92. PubMed ID: 24196653
[TBL] [Abstract][Full Text] [Related]
7. Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain.
Sicras-Mainar A; Rejas J; Navarro-Artieda R; Aguado-Jodar A; Ruiz-Torrejón A; Ibáñez-Nolla J; Kvasz M
BMC Urol; 2013 Oct; 13():51. PubMed ID: 24144225
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms.
Grenabo L; Herschorn S; Kaplan SA; Cardozo L; Scholfield D; Arumi D; Carlsson M; Chapman D; Ntanios F
Curr Med Res Opin; 2017 Oct; 33(10):1731-1736. PubMed ID: 28758802
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis.
Nazir J; Kelleher C; Aballéa S; Maman K; Hakimi Z; Mankowski C; Odeyemi I
Neurourol Urodyn; 2018 Mar; 37(3):986-996. PubMed ID: 29140559
[TBL] [Abstract][Full Text] [Related]
10. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms.
Ho CH; Chang TC; Lin HH; Liu SP; Huang KH; Yu HJ
J Formos Med Assoc; 2010 Oct; 109(10):702-8. PubMed ID: 20970066
[TBL] [Abstract][Full Text] [Related]
11. Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin.
Tijnagel MJ; Scheepe JR; Blok BF
BMC Urol; 2017 Apr; 17(1):30. PubMed ID: 28403849
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
[TBL] [Abstract][Full Text] [Related]
13. Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.
Cetinel B; Onal B; Gultekin MH; Guzelsoy M; Turegun FA; Dincer M
Int Urol Nephrol; 2019 Mar; 51(3):417-424. PubMed ID: 30725387
[TBL] [Abstract][Full Text] [Related]
14. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
[TBL] [Abstract][Full Text] [Related]
15. Psychometric assessment of female overactive bladder syndrome and antimuscarinics-related effects.
Hsiao SM; Liao SC; Chen CH; Chang TC; Lin HH
Maturitas; 2014 Dec; 79(4):428-34. PubMed ID: 25238744
[TBL] [Abstract][Full Text] [Related]
16. A Nordic registry-based study of drug treatment patterns in overactive bladder patients.
Milsom I; Schiotz HA; Svensson M; Kilany S; Hansson F
Scand J Urol; 2019 Aug; 53(4):246-254. PubMed ID: 31195868
[No Abstract] [Full Text] [Related]
17. A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands.
Drake MJ; Bowditch S; Arbe E; Hakimi Z; Guelfucci F; Amri I; Nazir J
BMC Urol; 2017 May; 17(1):36. PubMed ID: 28532455
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Cardozo L; Thorpe A; Warner J; Sidhu M
BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
[TBL] [Abstract][Full Text] [Related]
19. Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents.
Lua LL; Pathak P; Dandolu V
Neurourol Urodyn; 2017 Nov; 36(8):2123-2131. PubMed ID: 28467609
[TBL] [Abstract][Full Text] [Related]
20. Adherence to fesoterodine in women with overactive bladder in routine clinical practice.
Simó M; Porta O; Pubill J; Castillo MT; Mora I; Huguet E; Ortega JA; Martínez E
Actas Urol Esp; 2015 May; 39(4):222-8. PubMed ID: 25442908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
